2025年针对COVID-19的抗病毒药物的开发:未满足的需求和未来的挑战
Daniele Focosi1, David J Sullivan2, Massimo Franchini3
1North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
Expert review of anti-infective therapy
|February 26, 2025
概括
针对COVID-19的有效抗病毒药物仍然有限,特别是对于免疫功能低下的患者. 本次审查建议改善药物制造和临床试验设计,以获得更好的抗病毒疗法来对抗SARS-CoV-2.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 制药科学 制药科学
背景情况:
- 制COVID-19大流行严重依赖于疫苗和感染诱导的免疫力.
- 针对SARS-CoV-2的抗病毒药物已显示出有限的疗效,特别是在免疫受损的个体中.
研究的目的:
- 审查COVID-19的小分子抗病毒药物和被动免疫疗法.
- 突出现有抗病毒策略的局限性和潜力.
- 为未来的抗病毒开发提出药物制造和临床试验设计的改进建议.
主要方法:
- 关于小分子抗病毒药物和被动免疫疗法的科学文献的综述.
- 对当前抗病毒药物的局限性和未开发潜力的分析.
- 关于优化抗病毒药物开发和临床试验的专家意见的综合.
主要成果:
- 现有的抗病毒药物类别在治疗SARS-CoV-2感染方面存在局限性.
- 被动免疫疗法也对广泛应用提出了挑战.
- 分子和血清检测可以提高治疗的适当性.
结论:
- 需要在抗病毒药物制造和COVID-19临床试验设计方面进行范式转变.
- 结合不同类型的抗病毒疗法,可以提高疗效,同时保持成本效益.
- 呼吸道输送方法需要在临床试验中进行进一步的研究,以提高治疗结果.
相关概念视频
Retrovirus Life Cycles
45.6K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.6K
Viral Mutations
32.1K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.1K


